Document Detail


A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma.
MedLine Citation:
PMID:  7718335     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
9 patients with stage IV neuroblastoma were treated with 19 courses of human/mouse chimeric monoclonal antiganglioside GD2 antibody ch14.18 at dose levels of 30, 40 and 50 mg/m2/day for 5 days per course. The maximum tolerated dose (MTD) per injection was 50 mg/m2/day. 7 patients received more than one course of treatment, and none revealed any human anti-mouse antibody (HAMA) response. Clinical side-effects of patients treated with ch14.18 were abdominal and joint pains, pruritus and urticaria. One patient presented with a transient pupillatonia, while 2 others showed a unilateral atrophy of the optical nerve that was probably attributable to prior therapies. A complete remission was seen in 2 patients, partial remission in 2 patients, a minor response in 1 patient and stable disease in 1 patient. 3 patients showed tumour progression. Thus, our results indicate that treatment with chimeric MAb ch14.18 can elicit some complete and partial tumour responses in neuroblastoma patients.
Authors:
R Handgretinger; K Anderson; P Lang; R Dopfer; T Klingebiel; M Schrappe; P Reuland; S D Gillies; R A Reisfeld; D Neithammer
Related Documents :
6832495 - Hereditary motor sensory neuropathies in childhood.
1766455 - Role of electromyography in amyotrophic lateral sclerosis.
15015005 - Progressive idiopathic axonal neuropathy--a comparative clinical and histopathological ...
18382295 - Diplopia after balloon compression of retrogasserian ganglion rootlets for trigeminal n...
21770855 - Tandem plasmapheresis and hemodialysis: efficacy and safety.
14565795 - Multivitamin supplements may affect warfarin anticoagulation in susceptible patients.
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  European journal of cancer (Oxford, England : 1990)     Volume:  31A     ISSN:  0959-8049     ISO Abbreviation:  Eur. J. Cancer     Publication Date:  1995  
Date Detail:
Created Date:  1995-05-24     Completed Date:  1995-05-24     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  9005373     Medline TA:  Eur J Cancer     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  261-7     Citation Subset:  IM    
Affiliation:
Department of Paediatric Haematology, Children's Hospital, Tübingen, F.R.G.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
3-Iodobenzylguanidine
Animals
Antibodies, Monoclonal / blood,  therapeutic use*
Child
Child, Preschool
Female
Gangliosides / immunology*
Hemolysis
Humans
Iodine Radioisotopes / diagnostic use
Iodobenzenes / diagnostic use
Male
Mice
Neuroblastoma / blood,  radionuclide imaging,  therapy*
Grant Support
ID/Acronym/Agency:
CA42508/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Gangliosides; 0/Iodine Radioisotopes; 0/Iodobenzenes; 65988-71-8/ganglioside, GD2; 77679-27-7/3-Iodobenzylguanidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A new 123I-MIBG whole body scan scoring method--application to the prediction of the response of met...
Next Document:  Fanconi anaemia research: current status and prospects.